Skip to main content
Fig. 1 | Pediatric Rheumatology

Fig. 1

From: Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Fig. 1

Inflammatory markers are modified in patients with systemic juvenile idiopathic arthritis associated macrophage activation syndrome while treated with tocilizumab, compared to the untreated patients

Plots show a) serum ferritin levels, b) serum TG levels c) serum CRP levels, d) platelets count, e) plasma fibrinogen levels, and f) serum AST levels. Plots show median values. * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001.

Back to article page